Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | BRS3 | P32247 | 1/20 | 0.53 |
| ▸ | NMBR | P28336 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169323 | 0.98 | OPRM1 (0.62) | OPRM1OPRD1KMT2AMEN1KDM4E | |
| SCHEMBL29564909 | 0.96 | OPRM1 (0.63) | OPRM1OPRD1GHSR | |
| SCHEMBL30051966 | 0.96 | OPRM1 (0.65) | OPRM1OPRD1MMEBRS3NMBR | |
| SCHEMBL30052868 | 0.95 | KDM4E (0.60) | OPRM1OPRD1KMT2AMEN1KDM4E | |
| SCHEMBL30578461 | 0.94 | OPRM1 (0.70) | OPRM1OPRD1 | |
| SCHEMBL29564618 | 0.93 | OPRM1 (0.63) | OPRM1OPRD1KMT2AMEN1KDM4E | |
| SCHEMBL29658149 | 0.92 | OPRM1 (0.61) | OPRM1OPRD1KMT2AMEN1KDM4E | |
| SCHEMBL31016727 | 0.91 | KDM4E (0.58) | OPRM1OPRD1KMT2AMEN1KDM4E | |
| SCHEMBL7588967 | 0.90 | OPRM1 (0.71) | OPRM1OPRD1 | |
| SCHEMBL29828681 | 0.90 | KDM4E (0.57) | OPRM1OPRD1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | OPRM1 804/4885OPRD1 402/4885KMT2A 1801/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | OPRM1 2130/4885OPRD1 2937/4885KMT2A 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.